United States - English - NLM (National Library of Medicine)

xgen pharmaceuticals djb, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 10 ml - amphotericin b for injection usp should be administered primarily to patients with progressive, potentially life-threatening fungal infections. this potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. amphotericin b for injection usp is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), north american blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera absidia , mucor and rhizopus , and infections due to related susceptible species of conidiobolus and basidiobolus , and sporotrichosis. amphotericin b may be useful in the treatment of american mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. this product is contraindicated in those patients who have shown hypersensitivity to amphote

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b liposome for injection is indicated for the following: - empirical therapy for presumed fungal infection in febrile, neutropenic patients. - treatment of cryptococcal meningitis in hiv infected patients (see description of clinical studies) . - treatment of patients with aspergillus species, candida species and/or cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin b deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate. - treatment of visceral leishmaniasis. in immunocompromised patients with visceral leishmaniasis treated with amphotericin b liposome for injection, relapse rates were high following initial clearance of parasites (see description of clinical studies) . see dosage and administration for recommended doses by indication. amphotericin b liposome for injection is contraindicated in those patients who have demonstrated or have known hypersensiti

United States - English - NLM (National Library of Medicine)

eugia us llc - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b liposome for injection is indicated for the following: - empirical therapy for presumed fungal infection in febrile, neutropenic patients. - treatment of cryptococcal meningitis in hiv-infected patients (see description of clinical studies ). - treatment of patients with aspergillus species, candida species and/or cryptococcus species infections (see above for the treatment of cryptococcal meningitis) refractory to amphotericin b deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate. - treatment of visceral leishmaniasis. in immunocompromised patients with visceral leishmaniasis treated with amphotericin b liposome for injection, relapse rates were high following initial clearance of parasites (see description of clinical studies ). see dosage and administration   for recommended doses by indication. eleven clinical studies supporting the efficacy and safety of amphotericin b were conducted. this clinical program include

Kenya - English - Pharmacy and Poisons Board

asence pharma private limited sarabhai campus dr. vikram sarabhai marg wadi - amphotericin b - injection - amphotericin 50mg - antimycotics for systemic use: antibiotics

Canada - English - Health Canada

sterimax inc - amphotericin b - powder for solution - 50mg - amphotericin b 50mg - polyenes

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral le

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.

Israel - English - Ministry of Health

gilead sciences israel ltd - amphotericin b - powder for concentrate for infusion - amphotericin b 50 mg/vial - amphotericin b - amphotericin b - antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin b in effective dosages. this drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with aids or cancer). ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. hiv positive). empirical treatment of presumed fungal infection in febrile neutropenic patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - amphotericin b (amphotericin) -

Ireland - English - HPRA (Health Products Regulatory Authority)

gilead sciences ireland uc - amphotericin b - concentrate for solution for infusion - 50 milligram(s) - antibiotics; amphotericin b